Literature DB >> 2387394

Prediction of arenavirus fusion peptides on the basis of computer analysis of envelope protein sequences.

S E Glushakova1, I S Lukashevich, L A Baratova.   

Abstract

Theoretical search and selection criteria for putative fusion peptides of enveloped viruses are proposed. Arenavirus fusion peptides are predicted on the basis of computer-assisted analysis of amino acid sequences of arenavirus envelope proteins and elements of their secondary and tertiary structure. Accordingly, two regions of GP2 surface protein from 5 viruses of Arenaviridae family have been detected with properties typical of fusion peptides of other enveloped viruses. One region, named peptide IV, located at the N-terminus of the GP2 protein, is followed by the other region or peptide V, more likely candidate for the arenavirus fusion peptide.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2387394     DOI: 10.1016/0014-5793(90)81140-j

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein.

Authors:  O Lenz; J ter Meulen; H Feldmann; H D Klenk; W Garten
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P.

Authors:  Winfried R Beyer; Dennis Pöpplau; Wolfgang Garten; Dorothee von Laer; Oliver Lenz
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP.

Authors:  Magali E Droniou-Bonzom; Therese Reignier; Jill E Oldenburg; Alex U Cox; Colin M Exline; Jessica Y Rathbun; Paula M Cannon
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

4.  Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins.

Authors:  Bruno Eschli; Katharina Quirin; Alexander Wepf; Jacqueline Weber; Rolf Zinkernagel; Hans Hengartner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Characterization of Lassa virus glycoprotein oligomerization and influence of cholesterol on virus replication.

Authors:  Katrin Schlie; Anna Maisa; Frank Lennartz; Ute Ströher; Wolfgang Garten; Thomas Strecker
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

6.  Investigation of clade B New World arenavirus tropism by using chimeric GP1 proteins.

Authors:  Vanessa K Martin; Magali E Droniou-Bonzom; Therese Reignier; Jill E Oldenburg; Alex U Cox; Paula M Cannon
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

Review 7.  Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses.

Authors:  Sheli R Radoshitzky; Jens H Kuhn; Fabian de Kok-Mercado; Peter B Jahrling; Sina Bavari
Journal:  Expert Opin Drug Discov       Date:  2012-05-19       Impact factor: 6.098

8.  Genetic diversity among Lassa virus strains.

Authors:  M D Bowen; P E Rollin; T G Ksiazek; H L Hustad; D G Bausch; A H Demby; M D Bajani; C J Peters; S T Nichol
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

9.  A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.

Authors:  Ricardo Carrion; Jean L Patterson; Curtis Johnson; Monica Gonzales; Carmen R Moreira; Anysha Ticer; Kathleen Brasky; Gene B Hubbard; Dmitry Moshkoff; Juan Zapata; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2007-02-27       Impact factor: 3.641

10.  Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism.

Authors:  Eric M Vela; Lihong Zhang; Tonya M Colpitts; Robert A Davey; Judith F Aronson
Journal:  Virology       Date:  2007-08-14       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.